Apogee Therapeutics shares fall 1.66% in premarket after profit-taking and technical selling.

Apogee Therapeutics, Inc. fell 1.66% in premarket trading, following a 50% surge after the release of APEX Phase 2 data on July 7, as investors took profits, causing the stock to drop over 15% from its high. The EASI-75 response rate for APG777 was 66.9%, while similar to existing treatments like Dupixent and Ebglyss, raised competition concerns. The stock also broke below its 200-day moving average, triggering technical selling.